Technical Analysis for SYBX - Synlogic, Inc.

Grade Last Price % Change Price Change
grade F 2.19 0.92% 0.02
SYBX closed up 4.33 percent on Tuesday, October 15, 2019, on 29 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical SYBX trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.92%
Wide Bands Range Expansion 0.92%
Wide Bands Range Expansion 5.29%
20 DMA Resistance Bearish 1.39%
1,2,3 Retracement Bearish Bearish Swing Setup 1.39%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.39%
Wide Bands Range Expansion 1.39%
Doji - Bearish? Reversal 0.92%
Wide Bands Range Expansion 0.92%
Wide Bands Range Expansion 1.86%

Older signals for SYBX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.
Cancer Biology Disease Diabetes Obesity Inflammatory Bowel Disease Inborn Errors Of Metabolism Synthetic Biology Phenylketonuria Intellectual Disability Pku Rare Genetic Diseases
Is SYBX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 11.43
52 Week Low 1.96
Average Volume 230,555
200-Day Moving Average 6.7499
50-Day Moving Average 3.0023
20-Day Moving Average 2.2363
10-Day Moving Average 2.122
Average True Range 0.2019
ADX 41.1
+DI 14.5359
-DI 26.0819
Chandelier Exit (Long, 3 ATRs ) 2.1843
Chandelier Exit (Short, 3 ATRs ) 2.5657
Upper Bollinger Band 2.5734
Lower Bollinger Band 1.8992
Percent B (%b) 0.4
BandWidth 30.148012
MACD Line -0.2648
MACD Signal Line -0.339
MACD Histogram 0.0742
Fundamentals Value
Market Cap 35.33 Million
Num Shares 16.3 Million
EPS -9.33
Price-to-Earnings (P/E) Ratio -0.23
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.35
Resistance 3 (R3) 2.34 2.28 2.32
Resistance 2 (R2) 2.28 2.23 2.28 2.31
Resistance 1 (R1) 2.22 2.20 2.25 2.23 2.30
Pivot Point 2.16 2.16 2.17 2.16 2.16
Support 1 (S1) 2.10 2.11 2.13 2.11 2.04
Support 2 (S2) 2.04 2.08 2.04 2.03
Support 3 (S3) 1.98 2.04 2.02
Support 4 (S4) 1.99